Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $220
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Equal-Weight rating on Insulet (NASDAQ:PODD) and raises the price target from $200 to $220.
August 12, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Matt Miksic maintains an Equal-Weight rating on Insulet and raises the price target from $200 to $220.
The raised price target from $200 to $220 by Barclays suggests a positive outlook for Insulet, which could lead to a short-term increase in stock price. However, the Equal-Weight rating indicates a neutral stance, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100